ENTRY       D09980                      Drug
NAME        Trastuzumab emtansine (USAN/INN);
            Trastuzumab emtansine (genetical recombination) (JAN);
            Ado-trastuzumab emtansine;
            Kadcyla (TN)
PRODUCT     KADCYLA (Genentech)
FORMULA     C6448H9948N1720O2012S44
EXACT_MASS  145075.67
MOL_WEIGHT  145165.1575
CLASS       Antineoplastic
             DG01918  Tyrosine kinase inhibitor
              DG01917  Receptor tyrosine kinase inhibitor
               DG03158  HER2 inhibitor
REMARK      Therapeutic category: 4291
            ATC code: L01FD03
            Product: D09980<JP/US>
EFFICACY    Antineoplastic, Tubulin polymerization inhibitor, Receptor tyrosine kinase inhibitor, Anti-HER2 antibody
  DISEASE   Breast cancer (HER2 positive) [DS:H00031]
  TYPE      Antibody-drug conjugate
TARGET      ERBB2* (HER2, CD340) [HSA_VAR:2064v1 2064v3] [HSA:2064] [KO:K05083]
            TUBB [HSA:10381 10382 10383 203068 347688 347733 7280 81027 84617] [KO:K07375]
  PATHWAY   hsa04012(2064)  ErbB signaling pathway
            hsa05200(2064)  Pathways in cancer
            hsa05224(2064)  Breast cancer
INTERACTION  
STR_MAP     map07045  Antineoplastics - protein kinase inhibitors
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
                L01FD HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors
                 L01FD03 Trastuzumab emtansine
                  D09980  Trastuzumab emtansine (USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Monoclonal Antibody/Antibody-Drug Conjugate
               Ado-Trastuzumab Emtansine
                D09980  Trastuzumab emtansine (USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             4  Agents affecting cellular function
              42  Antineoplastics
               429  Miscellaneous
                4291  Other Antitumors
                 D09980  Trastuzumab emtansine (USAN/INN); Trastuzumab emtansine (genetical recombination) (JAN)
            Drug groups [BR:br08330]
             Antineoplastic
              DG01918  Tyrosine kinase inhibitor
               DG01917  Receptor tyrosine kinase inhibitor
                DG03158  HER2 inhibitor
                 D09980  Trastuzumab emtansine
            Drug classes [BR:br08332]
             Antineoplastic
              DG03158  HER2 inhibitor
               D09980  Trastuzumab emtansine
            Target-based classification of drugs [BR:br08310]
             Protein kinases
              Receptor tyrosine kinases (RTK)
               EGFR family
                ERBB2* (HER2, CD340) [HSA_VAR:2064v1 2064v3]
                 D09980  Trastuzumab emtansine (USAN/INN) &lt;JP/US&gt;
             Not elsewhere classified
              Cellular process
               Cytoskeleton
                TUBB
                 D09980  Trastuzumab emtansine (USAN/INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D09980
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D09980
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D09980
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D09980
            Pharmacogenomic biomarkers [br08341.html]
             Somatic variations in targeted cancer therapies
              D09980
DBLINKS     CAS: 1018448-65-1
            PubChem: 135626701
///
